Form 4: Verona Pharma CFO Mark Hahn Sells Shares Under 10b5-1 Plan

Verona Pharma's CFO, Mark Hahn, executed sales of ordinary shares through a pre-arranged 10b5-1 trading plan.

Summary

• Mark Hahn, the Chief Financial Officer of Verona Pharma plc, sold ordinary shares of the company on August 12 and 13, 2024.
• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2024.
• On August 12, 2024, 1,600 ordinary shares were sold at a price of $3.13 each.
• On August 13, 2024, two transactions occurred: 394,664 shares were sold at a weighted average price of $3.2012, and 3,736 shares were sold at $3.25 each.
• Following these transactions, Hahn directly owns 14,939,688 ordinary shares.
• Hahn also has indirect ownership through Restricted Share Units representing a contingent right to receive 2,825,000 Ordinary Shares and 12,114,688 Ordinary Shares underlying ADSs.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions.

Industry Context

Sales by company insiders are common and often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, including those in the pharmaceutical sector like Verona Pharma, to utilize 10b5-1 trading plans.
• These plans are designed to allow insiders to sell company stock in a pre-arranged manner, mitigating concerns about trading on non-public information.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also see insider trading activity under similar plans.

Stakeholder Impact

• Shareholders may react to insider selling, although sales under a 10b5-1 plan are generally viewed as less concerning.
• The impact on employees, customers, suppliers, and creditors is likely minimal.

Key Dates